Trial Profile
Open-Label, Multiple-Dose, Efficacy, Safety, and Tolerability Study of Eteplirsen in Subjects With Duchenne Muscular Dystrophy Who Participated in Study 4658-US-201
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Eteplirsen (Primary)
- Indications Duchenne muscular dystrophy
- Focus Pharmacodynamics; Therapeutic Use
- Sponsors Sarepta Therapeutics
- 01 Jun 2018 Status changed from active, no longer recruiting to completed, according to results published in the Neurology.
- 11 May 2018 Results (n=12) assessing the efficacy, safety, and tolerability of 30 and 50 mg/kg of eteplirsen in patients with Duchenne muscular dystrophy, were published in the Neurology.
- 27 Dec 2017 Results from Study 201/202 presented in a Sarepta Therapeutics media release.